Optics News

LAS VEGAS — Visus Therapeutics completed one clinical trial for Brimochol PF, a once-daily drop for presbyopia, earlier this year and is currently enrolling patients for a second trial, a company executive said at Vision Expo West.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTF with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space.

Vyluma Inc. has announced that the FDA will review its new drug application for NVK002, a preservative-free, low-dose atropine eye drop for myopia in children aged 3 to 17 years.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care.

A study found that more than one in four U.S. adults aged 71 years and older are visually impaired, with increasing prevalence related to older age, less education, lower income, non-white race and Hispanic ethnicity.

NovaSight announced that it is launching CureSight, its digital therapy for amblyopia, to the U.S. market this month.

We ophthalmologists are all introduced to pinhole or small-aperture optics on the first day of our residency when we are taught how to measure visual acuity and refract a patient.

WASHINGTON — In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery meeting, Marjan Farid, MD, discusses the phase 2b study results of the presbyopia-correcting drop CSF-1 from Orasis.

Orasis Pharmaceuticals announced that its phase 3 trials showed patients treated with CSF-1 achieved a statistically significant three-line or more gain in distance-corrected near visual acuity with no loss of distance visual acuity.

In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its B-cell-depleting agent Uplizna reduced the severity of attacks in people with neuromyelitis optica spectrum disorder.